ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Geriatric Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,161Medicare Part D Prescriptions Filled, Including Refills
$585K Total Retail Price of All Prescriptions
294 Patients Receiving at Least One Drug in Part D
99%Patients 65 Years and Older
95% Subsidized Claims for Low-Income Patients

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume .

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category
AMLODIPINE BESYLATE 443 437
SIMVASTATIN 333 333
FUROSEMIDE 318 318
LISINOPRIL 301 301
DONEPEZIL HCL 281 275
NAMENDA 264 258
LEVOTHYROXINE SODIUM 243 243
POTASSIUM CHLORIDE 231 225
DIOVAN 206 206
WARFARIN SODIUM 176 176
GENERLAC 167 167
NOVOLOG 145 145
METOPROLOL TARTRATE 145 140
OMEPRAZOLE 143 143
ATORVASTATIN CALCIUM 139 139
MIRTAZAPINE 137 131
METFORMIN HCL 129 129
LANTUS 124 124
RISPERIDONE 116 116
SERTRALINE HCL 102 102
QUETIAPINE FUMARATE 98 98
HYDROCHLOROTHIAZIDE 98 98
DIVALPROEX SODIUM 91 91
LEVETIRACETAM 89 89
EXELON 85 82
CARVEDILOL 84 84
AMITIZA 83 83
TRAZODONE HCL 82 82
CLOPIDOGREL 82 82
LOSARTAN POTASSIUM 78 78
ALENDRONATE SODIUM 73 73
POLYETHYLENE GLYCOL 3350 70 70
HYDRALAZINE HCL 68 62
FAMOTIDINE 63 63
METOPROLOL SUCCINATE 62 62
PLAVIX 59 59
LIDODERM 58 58
GABAPENTIN 58 58
SINGULAIR 56 56
GALANTAMINE HBR 56 56
NEXIUM 55 47
TRAMADOL HCL 54 54
PROCRIT 54 54
NOVOLIN R 53 52
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.